Bonus BioGroup
Press Room

Sunday, 17 October 2021 04:24

A patent approval secures Bonus BioGroup protection for the exclusivity of use and commercialization in Europe, in addition to the US, of Engineered Nanoparticle Technology, which may enable the development of a variety of therapies for the accelerat

Rate this item
(0 votes)

A patent approval secures Bonus BioGroup protection for the exclusivity of use and commercialization in Europe, in addition to the US, of Engineered Nanoparticle Technology, which may enable the development of a variety of therapies for the acceleration of the repair of injured tissue or tissue loss


Bonus BioGroup (TASE: BONS) is a clinical-stage Israeli biotechnology company, engaged in research and development of biomedical tissue-engineered and cell therapy products.

Following an immediate report regarding the US patent approval[1] of a unique technology of engineered nanoparticles[2] (hereinafter: the "US Patent"), which, among other things, may accelerate the repair of injured tissue and the reconstruction of tissue loss using biologically active materials, which will be delivered with the help of engineered nanoparticles to the location where tissue injury or tissue loss has occurred (hereinafter: "Engineered Nanoparticle Technology"), Bonus BioGroup is pleased to announce that on October 13, 2021, a patent was issued in Europe on Engineered Nanoparticles Technology[3] (hereinafter: the "European Patent").

The Engineered Nanoparticle Technology allows Bonus BioGroup to develop various treatments designed to accelerate the repair of injured tissue or to restore tissue loss, including:

  • Bone restoration, bone repair, or the construction of blood vessels in and around the bone, using biologically active substances, which will be delivered with the help of engineered nanoparticles, to the location where bone injury or bone loss has occurred;
  • Restoration of injured tissue, which is not bone tissue, by means of a drug, which will be delivered with the help of engineered nanoparticles, to the location where tissue injury has occurred.

Engineered Nanoparticle Technology is based, among other things, on chemistry, biotechnology and materials engineering.

The European Patent, together with the US Patent, secures the company protection until May 20, 2033, on the exclusivity of the use and commercialization in the US and Europe of the Engineered Nanoparticle Technology for biotechnological applications, in general, and for living tissue engineering of human tissue, for use in a variety of rehabilitative indications. Usage of this technology will be made according to an agreement between Bonus Therapeutics Ltd., a wholly owned subsidiary of the company, and Bar Ilan Research and Development Company Ltd. (hereinafter: "Bar Ilan"), affiliated with Bar Ilan University, Ramat Gan[4].

Bonus BioGroup uses a variety of unique technologies and knowledge, some of which were or are currently developed by the company, and some of which form part of the company's rich intellectual property, including seven families of patents and patent applications, comprising 25 approved patents, and 20 patent applications, in many countries around the world.

Sincerely,

Bonus BioGroup

By: Yossi Rauch (Chairman of the Board) and Dr. Shai Meretzki (CEO and Director)

 

[1] Report dating December 18, 2017 (reference 2017-01-117267).

[2] US patent 9,884,880, and US patent (continuation) 10,508,16.

[3] European patent 13794482.3.

[4] For further details, refer to report dating December 6, 2015 (reference: 2015-01-173130).

Read 297 times Last modified on Thursday, 28 October 2021 04:25

FOR MORE INVESTOR RELATION INFORMATION

Press Release, Announcements publication and more

Bonus BioGroup

Image

 

Terms of UsePrivacy Policy | Login        

© 2021 Bonus BioGroup Ltd. All Rights Reserved. Designed By Netron Israel Ltd.